BioLargo (BioLargo) Cash And Cash Equivalents : $3.54 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is BioLargo Cash And Cash Equivalents?

BioLargo's quarterly cash and cash equivalents declined from Jun. 2023 ($3.58 Mil) to Sep. 2023 ($3.04 Mil) but then increased from Sep. 2023 ($3.04 Mil) to Dec. 2023 ($3.54 Mil).

BioLargo's annual cash and cash equivalents increased from Dec. 2021 ($0.96 Mil) to Dec. 2022 ($1.85 Mil) and increased from Dec. 2022 ($1.85 Mil) to Dec. 2023 ($3.54 Mil).

BioLargo Cash And Cash Equivalents Historical Data

The historical data trend for BioLargo's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo Cash And Cash Equivalents Chart

BioLargo Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.66

0.72

0.96

1.85

3.54

BioLargo Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															1.85	3.26	3.58	3.04	3.54

BioLargo Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BioLargo (OTCPK:BLGO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BioLargo Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioLargo's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLargo (BioLargo) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

14921 Chestnut Street, Westminster, CA, USA, 92683

Website

https://www.biolargo.com

BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.

Executives

Linda Park	director	14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray	director	PO BOX 234, FREDERICK CO 80530
Jack B. Strommen	director	7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii	director	1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan	director	30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall	director	3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert	director, 10 percent owner, officer: Chief Executive Officer	3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc	10 percent owner	16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan	officer: Chief Financial Officer	8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano	director, officer: Corporate Secretary	3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc.	10 percent owner	2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code	10 percent owner	16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox	director	3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison	director
Eduardo Ruiz	director, 10 percent owner